WO2010115612A2 - Pregabalin compositions - Google Patents
Pregabalin compositions Download PDFInfo
- Publication number
- WO2010115612A2 WO2010115612A2 PCT/EP2010/002172 EP2010002172W WO2010115612A2 WO 2010115612 A2 WO2010115612 A2 WO 2010115612A2 EP 2010002172 W EP2010002172 W EP 2010002172W WO 2010115612 A2 WO2010115612 A2 WO 2010115612A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pregabalin
- blend
- parts
- pregelatinized starch
- capsule
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 229960001233 pregabalin Drugs 0.000 title claims abstract description 71
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title claims description 50
- 229920000881 Modified starch Polymers 0.000 claims abstract description 29
- 239000002775 capsule Substances 0.000 claims abstract description 25
- -1 pregabalin compound Chemical class 0.000 claims abstract description 24
- 239000000314 lubricant Substances 0.000 claims abstract description 16
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 14
- 239000008101 lactose Substances 0.000 claims abstract description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 9
- 239000007787 solid Substances 0.000 claims abstract description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 6
- 229930195725 Mannitol Natural products 0.000 claims abstract description 6
- 239000000594 mannitol Substances 0.000 claims abstract description 6
- 235000010355 mannitol Nutrition 0.000 claims abstract description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 5
- 229920002472 Starch Polymers 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 235000000346 sugar Nutrition 0.000 claims description 8
- 239000000454 talc Substances 0.000 claims description 8
- 229910052623 talc Inorganic materials 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 3
- 229940100691 oral capsule Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 18
- 229960001375 lactose Drugs 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- 235000019759 Maize starch Nutrition 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 229940009697 lyrica Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
Definitions
- the present invention relates to pharmaceutically acceptable compositions and dosage forms comprising pregabalin.
- Pregabalin S- (+)-4-amino-3- (2-methylpropyl) butanoic acid of the formula (1) is a structural analogue of gamma-aminobutyric acid (GABA).
- GABA gamma-aminobutyric acid
- Pregabalin acts as a modulator of voltage-gated calcium channels in the CNS, having the potential to treat neuropsychiatric disorders and pain.
- U.S. Pat. No. 6,197,819 discloses pregabalin and processes for its preparation.
- Pregabalin is an amino acid, i.e., it contains both a basic amino group and an acidic carboxy group, and thus in its free form can exist as a zwitterion (i.e., in a state where the carboxyl group is deprotonated and the primary amine moiety is protonated).
- Pregabalin may therefore form salts with both acids and bases; e.g., hydrochloride, hydrosulfates, etc., as well as sodium, potassium, etc.
- Pregabalin is currently marketed as a capsule for oral administration with brand name LYRIC A® by Pfizer.
- the capsule is filled by a powder blend comprising free base of pregabalin as the active moiety (25, 50, 75, 100, 150, 200, 225 or 300 mg per capsule), lactose monohydrate, maize starch and talc. It has been reported that pregabalin and lactose can react with each other via a Maillard reaction (see Lovdahl J. L. et al., "Synthesis and Characterisation of Pregabalin Lactose Conjugate Degradation Products," Journal of Pharmaceutical and Biomediacal Analysis 28 (2002), 917-924).
- a first aspect of the invention relates to a solid pharmaceutical blend, which comprises 100 parts of a pregabalin compound and at least 15 parts of a pregelatinized starch, wherein said blend is substantially free of lactose.
- the blend may further contain a lubricant, such as talc, and can be used in making a pharmaceutical unit dose of pregabalin.
- a second aspect of the invention relates to a pharmaceutical capsule-filling composition, which comprises a pregabalin compound, pregelatinized starch, and a lubricant; wherein said composition does not contain lactose, mannitol, or microcrystalline cellulose.
- Both the blend and the pharmaceutical composition can be formed into unit doses such as tablets, capsules, etc.
- Such medicaments can used in treating schizophrenia, epilepsy, neuropathic pain, fibromyalgia, generalised anxiety disorder, panic disorder and social phobia, by administering an effective amount of composition or dosage form of the present invention to a patient in need thereof.
- Pregabalin has poor handling properties, particularly concerning flowability, for processing into a pharmaceutical composition, typically a capsule. Therefore, a "dilution" of pregabalin with a suitable solid diluent is a useful tool for making a composition with suitable technological properties.
- the present invention is based on the discovery that pregelatinized starch is a most suitable excipient for pregabalin, even avoiding the degradation issues mentioned above.
- Pregabalin refers to S- (+)-4-amino-3- (2-methylpropyl) butanoic acid. Pregabalin is obtainable by known methods, such as those described in EPB 641 330. In free form, pregabalin is generally a crystalline compound but may be also prepared in an amorphous form (US Patent Application 20080014280). Crystalline forms of pregabalin may also comprise hydrated or solvated forms.
- the "pregabalin compound "as used herein is a free form of pregabalin or a pharmaceutically acceptable acid addition salt of pregabalin.
- a “pharmaceutically acceptable” salt is a salt in which the acid anion is not toxic to the human body to such an extent that it would affect the safety of the administration of pregabalin.
- a suitable pharmaceutically acceptable pregabalin salt may be pregabalin hydrochloride, pregabalin besylate or pregabalin tosylate.
- the pregabalin compound, and particularly the free form of pregabalin is advantageously formulated into the compositions of the present invention in a particulate state.
- the pregabalin compound particles to be formulated have a median diameter of less then 500 microns, more particularly less than 300 microns.
- Pregelatinized starch as used herein is a starch that has been chemically and/or mechanically processed to rupture all or part of the starch granules to yield a flowable and compressible powder.
- the "pregelatinized starch” in the compositions of the present inventions is a starch that corresponds to the respective monograph of Ph.Eur. or US Pharmacopoeia.
- Suitable particle size of the pregelatinized starch for making the composition of the present invention is a median diameter of less then 150 microns, preferably of about 50 microns.
- the composition of the invention is a solid pharmaceutical blend, which comprises 100 parts of a pregabalin compound and at least 15 parts of a pregelatinized starch.
- a pregelatinized starch is generally sufficient to provide the desired minimum flowability to the blend.
- the pregelatinized starch is contained in a proportion of 15 to 400 parts, preferably 20 to 200 parts per 100 parts of the pregabalin compound.
- the amount of pregabalin compound and pregelatinized starch in a composition of the invention is within the range of 20-85 weight % of pregabalin compound and 80-15 weight % of pregelatinized starch, based on the total weight of the composition, i.e., the blend, a capsule, etc.
- the blend is useful in forming pharmaceutical dosage forms such as capsules and tablets.
- Other excipients are typically combined therewith before the final dosage form is made; e.g., before filling the capsule or compressing a tablet.
- the blend can include additional excipients such as lubricants, etc., as are known in the art.
- additional excipients such as lubricants, etc., as are known in the art.
- the blend and all other compositions of the invention do not contain lactose, more preferably do not contain a reducible sugar, and in most cases contain no sugar; e.g., no mannitol.
- the term "sugar” as used herein refers to mono- and disaccharides and is not intended to cover polysaccharides.
- compositions of the invention that contain pregelatinized starch provide superior stability against the formation of pregabalin compound degradation products in comparison with similar blends comprising lactose, microcrystalline cellulose, or mannitol. Accordingly, preferred embodiments do not substantially contain these sugar or microcrystalline cellulose excipients; that is, such excipients are either not detectable or are present in such low amounts as to not adversely affect stability.
- the pregabalin compound and pregelatinized starch blend may be combined with other suitable excipients before making the final form comprising it. In particular, it may be combined with a lubricant.
- Typical lubricants include magnesium stearate, stearic acid and/or talc.
- the preferred lubricant is talc.
- the relative amount of the lubricant may be from 2 to.25 weight %, relative to the total weight of the composition.
- Additional excipients include starch such as corn/maize starch. Such diluent or filler excipients are typically present from 0 to 50 weight %, more typically from 1 to 30 weight %, including 10-25 weight %, based on the total weight of the composition.
- the solid blend of the invention can be made by normal pharmaceutical means for blending an active ingredient with an excipient.
- the blending is achieved by mixing in a suitable mixer and, optionally, milling and sieving the mixture to obtain a relative homogenous and intimate blend.
- the mixing can be done in one or more steps and can include additional excipients added in various orders; e.g., the pregabalin compound and pregelatinized starch do not have to be mixed first before additional excipients are added, though such is not excluded.
- the mixture of pregabalin compound and pregelatinized starch components may be granulated, with or without additional excipients, by means of wet or dry granulation, by processes known in the art, to form the blend in a form of a granulate.
- the granulate may be screened and/or milled to obtain a blend with suitable technological properties/sizes.
- the pharmaceutical blend typically in bulk form, is used to form a pharmaceutical capsule for oral dosing of pregabalin.
- a pharmaceutical capsule- filling composition generally comprises a pregabalin compound, pregelatinized starch, and a lubricant; wherein the composition does not contain lactose, mannitol, or microcrystalline cellulose.
- the capsule-filling composition comprises, per 100 parts of the pregabalin compound, 15 to 400 parts of the pregelatinized starch, and 5 to 100 parts of the lubricant.
- the composition can contain starch or such other excipient(s) as may be useful.
- lactose and more preferably all sugars as well as microcrystalline cellulose are preferably not substantially present in the capsule-filling composition.
- the capsule-filling composition contains no more than 10% additional excipient(s) beyond the pregabalin compound, pregelatinized starch, lubricant, and optional starch.
- additional excipients are often preferred to not exceed 5%, in some cases not greater than 1 % and in many cases, the capsule-filling composition consists of the pregabalin compound, pregelatinized starch, lubricant, and optional starch.
- the ready-to-use filling mixture which again is generally made by conventional mixing techniques of the dry or solid components, can be filled into a capsule, particularly a gelatine capsule, of a proper size.
- a capsule particularly a gelatine capsule
- 20 to 1000 mg of the filling mixture is filled per capsule, thus obtaining a single dosage form comprising the therapeutically effective or desirable amount of pregabalin.
- the capsule may comprise from 10 to 500 mg of pregabalin within the mixture, particularly 25, 50, 75, 100, 150, 200, 225 or 300 mg of pregabalin per capsule.
- the pharmaceutical compositions and dosage form of the present invention may be used in treating various diseases and conditions, towards which the pregabalin is active ("pregabalin- treatable diseases"), such as treating epilepsy, schizophrenia, neuropsychiatric disorders (e.g. generalized anxiety disorder, panic disorder, social phobia), and pain incl. neuropathic pain, fibromyalgia and acute herpetic and postherpetic pain.
- pregabalin- treatable diseases such as treating epilepsy, schizophrenia, neuropsychiatric disorders (e.g. generalized anxiety disorder, panic disorder, social phobia), and pain incl. neuropathic pain, fibromyalgia and acute herpetic and postherpetic pain.
- the treatment comprises administering an effective amount (e.g. a pain relieving amount) of the pregabalin composition of the present invention to a patient in need thereof.
- a blend comprising 25 % of pregabalin, 20% of starch, 20 % of talc and 35 % of another excipient (the variable excipient) as listed below were prepared and filled into the Size 0 gelatine capsules.
- a pregabalin capsule dosage form was prepared as follows:
- Pregabalin 100 % Pregabalin was sieved and blended with pregelatinized starch (Starch 1500) to a homogeneous blend. To the blend, talc (Super 60) was added and the mixture was blended again. The final mixture was filled in a Size 0 capsule in an amount of 400 mg of the blend per capsule (300 mg of pregabalin per capsule).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a solid pharmaceutical blend which comprises 100 parts of a pregabalin compound and at least 15 parts of a pregelatinized starch, wherein said blend is substantially free of lactose, and to a pharmaceutical capsule filling composition, which comprises a pregabalin compound, pregelatinized starch, and a lubricant; wherein said composition does not contain lactose, mannitol, or microcrystalline cellulose.
Description
PREGABALIN COMPOSITIONS
Background of the Invention
The present invention relates to pharmaceutically acceptable compositions and dosage forms comprising pregabalin.
Pregabalin, S- (+)-4-amino-3- (2-methylpropyl) butanoic acid of the formula (1)
is a structural analogue of gamma-aminobutyric acid (GABA). Pregabalin acts as a modulator of voltage-gated calcium channels in the CNS, having the potential to treat neuropsychiatric disorders and pain. U.S. Pat. No. 6,197,819 discloses pregabalin and processes for its preparation. Pregabalin is an amino acid, i.e., it contains both a basic amino group and an acidic carboxy group, and thus in its free form can exist as a zwitterion (i.e., in a state where the carboxyl group is deprotonated and the primary amine moiety is protonated). Pregabalin may therefore form salts with both acids and bases; e.g., hydrochloride, hydrosulfates, etc., as well as sodium, potassium, etc.
Pregabalin is currently marketed as a capsule for oral administration with brand name LYRIC A® by Pfizer. The capsule is filled by a powder blend comprising free base of pregabalin as the active moiety (25, 50, 75, 100, 150, 200, 225 or 300 mg per capsule), lactose monohydrate, maize starch and talc.
It has been reported that pregabalin and lactose can react with each other via a Maillard reaction (see Lovdahl J. L. et al., "Synthesis and Characterisation of Pregabalin Lactose Conjugate Degradation Products," Journal of Pharmaceutical and Biomediacal Analysis 28 (2002), 917-924). Such reactions are between a primary amino-group and a reducible sugar to form a conjugate product. US 7,022,678 confirms that pregabalin undergoes a Maillard reaction with lactose and that the commercial product apparently contained the conjugate products and its degradants. Several of these pregabalin degradation products are taught in US 7,022,678 to be useful as pharmaceuticals themselves. Nonetheless, the regulatory rules generally require the content and variation over time of any degradation products in a marketed composition to be minimal in order to avoid risks in efficacy and safety. The sensitivity of pregabalin to lactose via a Maillard reaction is a disadvantage of the marketed LYRICA® compositions.
Thus, it would be desirable to find a solid pharmaceutically acceptable composition of pregabalin having an improved stability in solid state.
Summary of the Invention
The present invention relates to the discovery that pregelatinized starch is an appropriate excipient for formulating pregabalin. Accordingly, a first aspect of the invention relates to a solid pharmaceutical blend, which comprises 100 parts of a pregabalin compound and at least 15 parts of a pregelatinized starch, wherein said blend is substantially free of lactose. The blend may further contain a lubricant, such as talc, and can be used in making a pharmaceutical unit dose of pregabalin.
A second aspect of the invention relates to a pharmaceutical capsule-filling composition, which comprises a pregabalin compound, pregelatinized starch, and a lubricant; wherein said composition does not contain lactose, mannitol, or microcrystalline cellulose. Both the blend and the pharmaceutical composition can be formed into unit doses such as tablets, capsules, etc. Such medicaments can used in treating schizophrenia, epilepsy, neuropathic pain, fibromyalgia, generalised anxiety disorder, panic disorder and social phobia, by administering an effective amount of composition or dosage form of the present invention to a patient in need thereof.
Detailed Description of the Invention
Pregabalin has poor handling properties, particularly concerning flowability, for processing into a pharmaceutical composition, typically a capsule. Therefore, a "dilution" of pregabalin with a suitable solid diluent is a useful tool for making a composition with suitable technological properties. The present invention is based on the discovery that pregelatinized starch is a most suitable excipient for pregabalin, even avoiding the degradation issues mentioned above.
"Pregabalin" as used herein refers to S- (+)-4-amino-3- (2-methylpropyl) butanoic acid. Pregabalin is obtainable by known methods, such as those described in EPB 641 330. In free form, pregabalin is generally a crystalline compound but may be also prepared in an amorphous form (US Patent Application 20080014280). Crystalline forms of pregabalin may also comprise hydrated or solvated forms.
The "pregabalin compound "as used herein is a free form of pregabalin or a pharmaceutically acceptable acid addition salt of pregabalin. A "pharmaceutically acceptable" salt is a salt in which the acid anion is not toxic to the human body to such an extent that it would affect the safety of the administration of pregabalin. Advantageously, a suitable pharmaceutically acceptable pregabalin salt may be pregabalin hydrochloride, pregabalin besylate or pregabalin tosylate.
The pregabalin compound, and particularly the free form of pregabalin, is advantageously formulated into the compositions of the present invention in a particulate state. Typically the pregabalin compound particles to be formulated have a median diameter of less then 500 microns, more particularly less than 300 microns.
"Pregelatinized starch" as used herein is a starch that has been chemically and/or mechanically processed to rupture all or part of the starch granules to yield a flowable and compressible powder. In general, the "pregelatinized starch" in the compositions of the present inventions is a starch that corresponds to the respective monograph of Ph.Eur. or US Pharmacopoeia.
Suitable particle size of the pregelatinized starch for making the composition of the present invention is a median diameter of less then 150 microns, preferably of about 50 microns.
In a basic form, the composition of the invention is a solid pharmaceutical blend, which comprises 100 parts of a pregabalin compound and at least 15 parts of a pregelatinized starch. Such an amount of pregelatinized starch is generally sufficient to provide the desired minimum flowability to the blend. Typically, however, the
pregelatinized starch is contained in a proportion of 15 to 400 parts, preferably 20 to 200 parts per 100 parts of the pregabalin compound. Often the amount of pregabalin compound and pregelatinized starch in a composition of the invention is within the range of 20-85 weight % of pregabalin compound and 80-15 weight % of pregelatinized starch, based on the total weight of the composition, i.e., the blend, a capsule, etc. The blend is useful in forming pharmaceutical dosage forms such as capsules and tablets. Other excipients are typically combined therewith before the final dosage form is made; e.g., before filling the capsule or compressing a tablet. Accordingly, the blend can include additional excipients such as lubricants, etc., as are known in the art. But for stability concerns, it is preferred that the blend and all other compositions of the invention do not contain lactose, more preferably do not contain a reducible sugar, and in most cases contain no sugar; e.g., no mannitol. For clarity, the term "sugar" as used herein refers to mono- and disaccharides and is not intended to cover polysaccharides. Also the blend and other compositions of the invention preferably do not contain microcrystalline cellulose. As shown in Example 1 below, compositions of the invention that contain pregelatinized starch provide superior stability against the formation of pregabalin compound degradation products in comparison with similar blends comprising lactose, microcrystalline cellulose, or mannitol. Accordingly, preferred embodiments do not substantially contain these sugar or microcrystalline cellulose excipients; that is, such excipients are either not detectable or are present in such low amounts as to not adversely affect stability.
As mentioned above, the pregabalin compound and pregelatinized starch blend may be combined with other suitable excipients before making the final form comprising it. In particular, it may be combined with a lubricant. Typical lubricants include magnesium stearate, stearic acid and/or talc. The preferred lubricant is talc. The relative amount of the lubricant may be from 2 to.25 weight %, relative to the total weight of the composition. Additional excipients include starch such as corn/maize starch. Such diluent or filler excipients are typically present from 0 to 50 weight %, more typically from 1 to 30 weight %, including 10-25 weight %, based on the total weight of the composition. The solid blend of the invention can be made by normal pharmaceutical means for blending an active ingredient with an excipient. Typically the blending is achieved by mixing in a suitable mixer and, optionally, milling and sieving the mixture to obtain a relative homogenous and intimate blend. The mixing can be done in one or more steps and can include additional excipients added in various orders; e.g., the pregabalin compound and pregelatinized starch do not have to be mixed first before additional excipients are added, though such is not excluded. Alternatively, the mixture of pregabalin compound and pregelatinized starch components may be granulated, with or without additional excipients, by means of wet or dry granulation, by processes known in the art, to form the blend in a form of a granulate. The granulate may be screened and/or milled to obtain a blend with suitable technological properties/sizes.
Generally the pharmaceutical blend, typically in bulk form, is used to form a pharmaceutical capsule for oral dosing of pregabalin. Such a pharmaceutical capsule-
filling composition generally comprises a pregabalin compound, pregelatinized starch, and a lubricant; wherein the composition does not contain lactose, mannitol, or microcrystalline cellulose. Typically the capsule-filling composition comprises, per 100 parts of the pregabalin compound, 15 to 400 parts of the pregelatinized starch, and 5 to 100 parts of the lubricant. Additionally the composition can contain starch or such other excipient(s) as may be useful. Of course, lactose and more preferably all sugars as well as microcrystalline cellulose are preferably not substantially present in the capsule-filling composition. In some embodiments, the capsule-filling composition contains no more than 10% additional excipient(s) beyond the pregabalin compound, pregelatinized starch, lubricant, and optional starch. The use of a simple formulation is generally preferred and hence the presence of additional excipients is often preferred to not exceed 5%, in some cases not greater than 1 % and in many cases, the capsule-filling composition consists of the pregabalin compound, pregelatinized starch, lubricant, and optional starch.
The ready-to-use filling mixture, which again is generally made by conventional mixing techniques of the dry or solid components, can be filled into a capsule, particularly a gelatine capsule, of a proper size. In general, 20 to 1000 mg of the filling mixture is filled per capsule, thus obtaining a single dosage form comprising the therapeutically effective or desirable amount of pregabalin. The capsule may comprise from 10 to 500 mg of pregabalin within the mixture, particularly 25, 50, 75, 100, 150, 200, 225 or 300 mg of pregabalin per capsule.
The pharmaceutical compositions and dosage form of the present invention may be used in treating various diseases and conditions, towards which the pregabalin is
active ("pregabalin- treatable diseases"), such as treating epilepsy, schizophrenia, neuropsychiatric disorders (e.g. generalized anxiety disorder, panic disorder, social phobia), and pain incl. neuropathic pain, fibromyalgia and acute herpetic and postherpetic pain. In general, the treatment comprises administering an effective amount (e.g. a pain relieving amount) of the pregabalin composition of the present invention to a patient in need thereof.
The invention will be further described with reference to the following non- limiting examples.
Example 1
A blend comprising 25 % of pregabalin, 20% of starch, 20 % of talc and 35 % of another excipient (the variable excipient) as listed below were prepared and filled into the Size 0 gelatine capsules. The capsules were placed in an open dish at 4OC 1 15 % RH for two months and analysed. Assay and purity was measured at t = 0, t = 1 and t=2 months, using pregabalin as reference material. The content of the known lactam impurity (arisen from pregabalin) was calculated using the known response factor (RRF = 17); the other impurities were calculated as if having the RRF 1.0.
Results:
Example 2
A pregabalin capsule dosage form was prepared as follows:
Composition
Pregabalin 75 %
Pregelatinized starch 16.625 %
Talc 8.375 %
100 %
Pregabalin was sieved and blended with pregelatinized starch (Starch 1500) to a homogeneous blend. To the blend, talc (Super 60) was added and the mixture was blended again. The final mixture was filled in a Size 0 capsule in an amount of 400 mg of the blend per capsule (300 mg of pregabalin per capsule).
The invention having been described it will be obvious that the same may be varied in many ways and all such modifications are contemplated as being within the scope of the invention as defined by the following claims.
Claims
1. A solid pharmaceutical blend which comprises 100 parts of a pregabalin compound and at least 15 parts of a pregelatinized starch, wherein said blend is substantially free of lactose.
2. The blend according to claim 1, wherein said pregelatinized starch is contained in an amount within the range of 15 to 400 parts, preferably 20 to 200 parts.
3. The blend according to claim 1 or 2, wherein said pregabalin compound is pregabalin free form.
4. The blend according to claims 1-3, wherein said pregelatinized starch has a median diameter of less then 150 microns, preferably of about 50 microns.
5. The blend according to claims 1-4, wherein said blend is substantially free of a reducible sugar, and preferably said blend is substantially free of sugar.
6. The blend according to claims 1-5, wherein said blend is substantially free of microcrystalline cellulose.
7. The blend according to claims 1-6, which further comprises a lubricant, which lubricant is preferably talc.
8. A pharmaceutical capsule filling composition, which comprises a pregabalin compound, pregelatinized starch, and a lubricant; wherein said composition does not contain lactose, mannitol, or microcrystalline cellulose.
9. The pharmaceutical composition according to claim 8, wherein said composition comprises 100 parts of said pregabalin compound, 15 to 400 parts of said pregelatinized starch, and 5 to 100 parts of said lubricant.
10. The pharmaceutical composition according to claim 8 or 9, which further comprises starch.
11. An oral capsule comprising a therapeutically effective amount of the pharmaceutical composition according to claims 8-10.
12. The capsule according to claim 11 , wherein said capsule contains 10 to 500 mg of pregabalin, particularly, 25, 50, 75, 100, 150, 200, 225 or 300 mg of pregabalin per capsule.
13. Pharmaceutical blend of claims 1-7 or the pharmaceutical composition of claims 8-10, or the oral capsule of claims 11 or 12 for use in treating pregabalin-treatable diseases.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16836309P | 2009-04-10 | 2009-04-10 | |
US61/168,363 | 2009-04-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010115612A2 true WO2010115612A2 (en) | 2010-10-14 |
WO2010115612A3 WO2010115612A3 (en) | 2011-02-03 |
Family
ID=42691170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/002172 WO2010115612A2 (en) | 2009-04-10 | 2010-04-01 | Pregabalin compositions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010115612A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102793685A (en) * | 2012-08-14 | 2012-11-28 | 浙江华海药业股份有限公司 | Oral capsule containing pregabalin and preparation method thereof |
US9937153B2 (en) | 2013-08-30 | 2018-04-10 | Merck Sharp & Dohme Ltd. | Oral pharmaceutical formulation of omarigliptin |
JP2019142834A (en) * | 2017-07-31 | 2019-08-29 | 大原薬品工業株式会社 | Solid formulations containing pregabalin and suitable excipients |
CN112076176A (en) * | 2019-10-18 | 2020-12-15 | 杭州百诚医药科技股份有限公司 | Pregabalin capsule and preparation method thereof |
WO2024115889A1 (en) | 2022-11-28 | 2024-06-06 | Orbit Pharma Limited | Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
US7022678B2 (en) | 2001-03-30 | 2006-04-04 | Warner-Lambert Company | Pregabalin lactose conjugates |
US20080014280A1 (en) | 2006-07-17 | 2008-01-17 | Glenmark Pharmaceuticals Limited | Amorphous pregabalin and process for the preparation thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2373953A1 (en) * | 1999-07-02 | 2001-01-11 | Warner-Lambert Company | A synergistic combination: gabapentin and pregabalin |
EP1591107A1 (en) * | 2004-04-28 | 2005-11-02 | Pfizer GmbH Arzneimittelwerk Gödecke | Process for the selective increase of a release rate of an active material from a pharmaceutical composition |
WO2006121557A1 (en) * | 2005-05-10 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Pregabalin free of lactam and a process for preparation thereof |
DE102007019071A1 (en) * | 2007-04-23 | 2008-10-30 | Ratiopharm Gmbh | Stabilized pharmaceutical composition containing pregabalin |
-
2010
- 2010-04-01 WO PCT/EP2010/002172 patent/WO2010115612A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
US7022678B2 (en) | 2001-03-30 | 2006-04-04 | Warner-Lambert Company | Pregabalin lactose conjugates |
US20080014280A1 (en) | 2006-07-17 | 2008-01-17 | Glenmark Pharmaceuticals Limited | Amorphous pregabalin and process for the preparation thereof |
Non-Patent Citations (1)
Title |
---|
LOVDAHL J.L. ET AL.: "Synthesis and Characterisation of Pregabalin Lactose Conjugate Degradation Products", JOURNAL OF PHARMACEUTICAL AND BIOMEDIACAL ANALYSIS, vol. 28, 2002, pages 917 - 924 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102793685A (en) * | 2012-08-14 | 2012-11-28 | 浙江华海药业股份有限公司 | Oral capsule containing pregabalin and preparation method thereof |
US9937153B2 (en) | 2013-08-30 | 2018-04-10 | Merck Sharp & Dohme Ltd. | Oral pharmaceutical formulation of omarigliptin |
JP2019142834A (en) * | 2017-07-31 | 2019-08-29 | 大原薬品工業株式会社 | Solid formulations containing pregabalin and suitable excipients |
CN112076176A (en) * | 2019-10-18 | 2020-12-15 | 杭州百诚医药科技股份有限公司 | Pregabalin capsule and preparation method thereof |
WO2024115889A1 (en) | 2022-11-28 | 2024-06-06 | Orbit Pharma Limited | Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2010115612A3 (en) | 2011-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8974824B2 (en) | Lanthanum composition | |
US20070172521A1 (en) | Levetiracetam formulations and methods for their manufacture | |
JP5763063B2 (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic use | |
MX2007016072A (en) | Diclofenac formulations and methods of use. | |
US20060222703A1 (en) | Pharmaceutical composition and preparation method thereof | |
EP2148656A2 (en) | Stabilised pharmaceutical composition containing pregabaline | |
US8022104B2 (en) | Formulations of ladostigil tartrate | |
WO2010115612A2 (en) | Pregabalin compositions | |
JP2015527321A (en) | Laquinimod formulation without alkalizing agent | |
JP4853818B2 (en) | Solid formulation containing ibuprofen and ambroxol hydrochloride | |
US20210401748A1 (en) | Powder for oral suspension containing lamotrigine | |
US9682045B2 (en) | Stable pharmaceutical compositions of thyroid hormone drug | |
EP0689434B1 (en) | Pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof | |
JP6179515B2 (en) | Stabilized solid preparation for internal use | |
WO2015104666A2 (en) | Pharmaceutical composition of fingolimod | |
JP2015107951A (en) | Granules | |
CN111954518B (en) | Dry pharmaceutical powder composition for inhalation comprising thyroid hormone | |
TWI536992B (en) | And a medicinal composition for oral administration of improved elution and / or absorption | |
WO2015158463A1 (en) | Stable pharmaceutical dosage forms comprising levothyroxine sodium | |
RU2174836C1 (en) | Pharmaceutical composition eliciting analgesic effect | |
JP2006117544A (en) | Solid preparation for internal use containing ambroxol hydrochloride | |
WO2019030773A1 (en) | Low-dose diclofenac compositions | |
JP2004123591A (en) | Solid preparation for treating rhinitis | |
SK2022010U1 (en) | Stable composition of pregabalin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10712021 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10712021 Country of ref document: EP Kind code of ref document: A2 |